/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Cardiff Oncology Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.13 0.0441(4.41%) CRDF at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 2.025
Highest Today 2.145
Today’s Open 2.065
Prev. Close 2.04
52 Week High 5.64
52 Week Low 1.90
Day’s Range: Low 2.025 High 2.145
52-Week Range: Low 1.90 High 5.64
1 day return -
1 Week return -6.79
1 month return -4.7
3 month return -0.23
6 month return -41.13
1 year return -11.82
3 year return +36.21
5 year return -89.7
10 year return -

Institutional Holdings

BlackRock Inc 5.92

Vanguard Group Inc 5.60

Blair William & Co 3.79

Pfizer Inc 3.63

Vanguard Total Stock Mkt Idx Inv 3.13

LAURION CAPITAL MANAGEMENT LP 2.70

Geode Capital Management, LLC 2.25

iShares Russell 2000 ETF 2.25

Adage Capital Partners Gp LLC 2.14

Millennium Management LLC 1.69

State Street Corp 1.69

Morgan Stanley - Brokerage Accounts 1.20

Northern Trust Corp 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.03

Fidelity Small Cap Index 0.93

Nuveen, LLC 0.84

Susquehanna International Group, LLP 0.80

Mccormack Advisors International 0.76

Two Sigma Investments LLC 0.67

CREF Stock R3 0.67

Bank of New York Mellon Corp 0.50

Fidelity Extended Market Index 0.50

iShares Russell 2000 Value ETF 0.46

Marshall Wace Asset Management Ltd 0.45

Vanguard Russell 2000 ETF 0.44

iShares Russell 2000 Growth ETF 0.38

Two Sigma Advisers, LLC 0.31

Northern Small Cap Value 0.30

NT Quality Small Cap Value 0.30

UBS Group AG 0.30

Royal Bank of Canada 0.29

Schwab Small Cap Index 0.24

NT R2000 Index Fund - NL 0.23

iShares Micro-Cap ETF 0.21

State St Russell Sm Cap® Indx SL Cl I 0.19

Extended Equity Market Fund K 0.19

NT R2000 Index Fund - DC - NL - 3 0.18

Fidelity Total Market Index 0.17

SPDR® Russell 2000 US Small Cap ETF 0.17

Vanguard US Momentum Factor ETF 0.15

Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 137.42 M

PB Ratio 2.989

PE Ratio 0.0

Enterprise Value 86.25 M

Total Assets 97.19 M

Volume 837657

Company Financials

Annual Revenue FY23:460000 0.5M, FY22:386000 0.4M, FY21:359000 0.4M, FY20:365993 0.4M, FY19:245000 0.2M

Annual Profit FY23:null 0.0M, FY22:386000 0.4M, FY21:359000 0.4M, FY20:365993 0.4M, FY19:245000 0.2M

Annual Net worth FY23:-40801000 -40.8M, FY22:-37506000 -37.5M, FY21:-27742000 -27.7M, FY20:-19279947 -19.3M, FY19:-16152000 -16.2M

Quarterly Revenue Q3/2025:120000 0.1M, Q2/2025:121000 0.1M, Q1/2025:109000 0.1M, Q3/2024:165000 0.2M, Q2/2024:163000 0.2M

Quarterly Profit Q3/2025:120000 0.1M, Q2/2025:-11459000 -11.5M, Q1/2025:109000 0.1M, Q3/2024:165000 0.2M, Q2/2024:58000 0.1M

Quarterly Net worth Q3/2025:-11258000 -11.3M, Q2/2025:-13943000 -13.9M, Q1/2025:-13434000 -13.4M, Q3/2024:-11855000 -11.9M, Q2/2024:-11778000 -11.8M

Fund house & investment objective

Company Information Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 32

Industry Biotechnology

CEO Dr. Mark Erlander Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow